This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Masubuchi, N. Articles by Atsumi, R. Search for Related Content PubMed PubMed Citation Articles by Masubuchi, N. Articles by Atsumi, R.

A Predictive Model of Human Myelotoxicity Using Five Camptothecin Derivatives and the In vitro Colony-Forming Unit Granulocyte/Macrophage Assay

¹ Drug Metabolism and Physicochemical Property Research Laboratory, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan; and ² Southern Research Institute, Birmingham, Alabama

Purpose: Many promising anticancer drugs are limited by myelosuppression. It is difficult to evaluate human myelotoxicity before a Phase I study because of the susceptibility of humans and animals to hematotoxicity. The purpose of this study was to establish a reliable method to predict the human maximum tolerated dose (MTD) of five camptothecin derivatives: SN-38, DX-8951f, topotecan, 9-aminocamptothecin, and camptothecin.

Experimental Design: The myelotoxicity of SN-38 and DX-8951f were evaluated on bone marrow from mice, dogs, and humans using a 14-day colony-forming unit, granulocyte-macrophage (CFU-GM) assay to determine the 50%, 75%, and 90% inhibitory concentration values (IC₅₀, IC₇₅, and IC₉₀, respectively).

Results: Species differences in myelotoxicity were observed for SN-38 and DX-8951f. Using human and murine IC₉₀s for myelotoxicity of these compounds and other camptothecin compounds (topotecan, 9-aminocamptothecin, and camptothecin), in vivo toxicological data, and pharmacokinetic parameters (data referred to in the literature), human MTDs were predicted retrospectively. The mechanism-based prediction model that is proposed uses the in vitro camptothecin assay and in vivo parameters on the basis of free fraction of area under the concentration-curve at the MTD (r² = 0.887) and suggests that the human MTDs were well predicted for the five camptothecin derivatives by this model rather than by other models.

Conclusion: The human MTDs of the camptothecin drugs were successfully predicted using the mechanism-based prediction model. The application of this model for in vitro hematotoxicology could play an important role for the development of new anticancer agents.

This article has been cited by other articles:

				B. A. Teicher In Vivo/Ex Vivo and In Situ Assays Used in Cancer Research: A Brief Review Toxicol Pathol, January 1, 2009; 37(1): 114 - 122. [Abstract] [Full Text] [PDF]

				L. S. Kurtzberg, T. Battle, C. Rouleau, R. G. Bagley, N. Agata, M. Yao, S. Schmid, S. Roth, J. Crawford, R. Krumbholz, et al. Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors Mol. Cancer Ther., October 1, 2008; 7(10): 3212 - 3222. [Abstract] [Full Text] [PDF]